Supplementary materials: Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry
Published: 16 April 2024| Version 1 | DOI: 10.17632/8bbwkw2xnd.1
Contributor:
Description
Supplementary materials related to the manuscript entitled “Dupilumab provides sustained effectiveness on patient-reported outcomes and favorable safety in patients with moderate-to-severe atopic dermatitis: up to 5-year results from the daily practice BioDay Registry”
Files
Institutions
Rijksuniversiteit Groningen
Categories
Atopic Dermatitis